Jwa Hoon Kim

973 total citations
30 papers, 348 citations indexed

About

Jwa Hoon Kim is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Jwa Hoon Kim has authored 30 papers receiving a total of 348 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 10 papers in Surgery. Recurrent topics in Jwa Hoon Kim's work include Gastrointestinal Tumor Research and Treatment (9 papers), Gastric Cancer Management and Outcomes (8 papers) and Colorectal Cancer Treatments and Studies (5 papers). Jwa Hoon Kim is often cited by papers focused on Gastrointestinal Tumor Research and Treatment (9 papers), Gastric Cancer Management and Outcomes (8 papers) and Colorectal Cancer Treatments and Studies (5 papers). Jwa Hoon Kim collaborates with scholars based in South Korea, Japan and United States. Jwa Hoon Kim's co-authors include Min‐Hee Ryu, Changhoon Yoo, Baek‐Yeol Ryoo, Yoon‐Koo Kang, Sook Ryun Park, Jae‐Lyun Lee, Young Soo Park, Inkeun Park, Deokhoon Kim and Sun‐Young Lee and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Lancet Oncology.

In The Last Decade

Jwa Hoon Kim

29 papers receiving 342 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jwa Hoon Kim South Korea	11	182	112	81	75	74	30	348
Evin Büyükünal Türkiye	13	197 1.1×	152 1.4×	103 1.3×	31 0.4×	70 0.9×	37	406
Kaan Helvacı Türkiye	9	242 1.3×	105 0.9×	88 1.1×	23 0.3×	43 0.6×	24	371
Katia Dotti Italy	12	364 2.0×	149 1.3×	99 1.2×	58 0.8×	114 1.5×	28	514
Wanli Liu China	11	244 1.3×	87 0.8×	78 1.0×	27 0.4×	59 0.8×	18	392
Richard M. Lee‐Ying Canada	10	168 0.9×	125 1.1×	78 1.0×	71 0.9×	58 0.8×	49	299
Ryoji Takada Japan	13	291 1.6×	143 1.3×	191 2.4×	73 1.0×	34 0.5×	63	454
Seigo Yukisawa Japan	12	165 0.9×	182 1.6×	152 1.9×	65 0.9×	16 0.2×	27	353
Francesca Erroi Italy	14	328 1.8×	189 1.7×	307 3.8×	27 0.4×	113 1.5×	32	587
Mitsuhito Sasaki Japan	12	323 1.8×	129 1.2×	245 3.0×	21 0.3×	51 0.7×	52	497
Angelika Bezan Austria	11	177 1.0×	159 1.4×	136 1.7×	14 0.2×	19 0.3×	16	389

Countries citing papers authored by Jwa Hoon Kim

Since Specialization

Citations

This map shows the geographic impact of Jwa Hoon Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jwa Hoon Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jwa Hoon Kim more than expected).

Fields of papers citing papers by Jwa Hoon Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jwa Hoon Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jwa Hoon Kim. The network helps show where Jwa Hoon Kim may publish in the future.

Co-authorship network of co-authors of Jwa Hoon Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Jwa Hoon Kim. A scholar is included among the top collaborators of Jwa Hoon Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jwa Hoon Kim. Jwa Hoon Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ajani, Jaffer A., Howard A. Burris, Crystal S. Denlinger, et al.. (2025). Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study. The Lancet Oncology. 26(7). 847–859. 5 indexed citations

Choi, Yonghwa, Jangwoo Lee, Keewon Shin, et al.. (2024). Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer. BMC Cancer. 24(1). 502–502. 3 indexed citations

Kim, Jwa Hoon, et al.. (2024). Phase Ib and pharmacokinetics study of alpelisib, a PIK3CA inhibitor, and capecitabine in patients with advanced solid tumors. Frontiers in Oncology. 14. 1390452–1390452. 6 indexed citations

Lee, Soo Hyun, Young Soo Park, Jwa Hoon Kim, et al.. (2022). Identification of Biomarkers Associated with Liver Metastasis Progression from Colorectal Cancer Using Exosomal RNA Profiling. Cancers. 14(19). 4723–4723. 4 indexed citations

Kim, Jwa Hoon, Changhoon Yoo, Seyoung Seo, et al.. (2022). A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY. Cancers. 14(3). 559–559. 16 indexed citations

Hyung, Jaewon, Eun Jeong Cho, Jihun Kim, et al.. (2022). Histopathologic and Molecular Biomarkers of PD-1/PD-L1 Inhibitor Treatment Response among Patients with Microsatellite Instability‒High Colon Cancer. Cancer Research and Treatment. 54(4). 1175–1190. 13 indexed citations

Kim, Jwa Hoon, Myung Han Hyun, Soo Hyun Lee, et al.. (2022). Blood transfusion has an adverse impact on the prognosis of patients receiving chemotherapy for advanced colorectal cancer: experience from a single institution with a patient blood management program. Supportive Care in Cancer. 30(6). 5289–5297. 3 indexed citations

Yoo, Changhoon, Jwa Hoon Kim, Min‐Hee Ryu, et al.. (2021). Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study. Liver Cancer. 10(2). 107–114. 68 indexed citations

Kim, Hyung‐Don, Hyeon-Su Im, Jwa Hoon Kim, et al.. (2021). Use of Gemcitabine plus Carboplatin is Associated with Poor Outcomes in Urothelial Carcinoma Patients with Chronic Kidney Disease Stage 4-5. Cancer Research and Treatment. 53(4). 1166–1173. 4 indexed citations

10.

Jeong, Hyehyun, Kye Jin Park, Hyung‐Don Kim, et al.. (2021). The Prognosis and the Role of Adjuvant Chemotherapy for Node-Positive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Surgery. Cancer Research and Treatment. 54(1). 226–233. 2 indexed citations

11.

Kim, Jwa Hoon, Seyoung Seo, Kyu‐pyo Kim, et al.. (2020). Rivaroxaban Versus Low-molecular-weight Heparin for Venous Thromboembolism in Advanced Upper Gastrointestinal Tract and Hepatopancreatobiliary Cancer. In Vivo. 34(2). 829–837. 14 indexed citations

12.

Kim, Hyung‐Don, Jwa Hoon Kim, Yeon‐Mi Ryu, et al.. (2020). Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3- CD4+ T Cells in Biliary Tract Cancer. Cancer Research and Treatment. 53(1). 162–171. 17 indexed citations

13.

Kim, Jwa Hoon, Jae Ho Jeong, Baek‐Yeol Ryoo, et al.. (2020). Adjuvant Chemotherapy for Resected Ampulla of Vater Carcinoma: Retrospective Analysis of 646 Patients. Cancer Research and Treatment. 53(2). 424–435. 5 indexed citations

14.

Kim, Jwa Hoon, Sun Young Kim, Kyu‐pyo Kim, et al.. (2019). Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study. Targeted Oncology. 14(6). 689–697. 5 indexed citations

15.

Kim, Jwa Hoon, Min‐Hee Ryu, Changhoon Yoo, et al.. (2019). Long‐term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14‐year, single‐center experience. Cancer Medicine. 8(3). 1034–1043. 11 indexed citations

16.

Kim, Jeong Eun, Sun Young Chae, Jwa Hoon Kim, et al.. (2019). 3′-Deoxy-3’-18F-Fluorothymidine and 18F-Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies. European Journal of Nuclear Medicine and Molecular Imaging. 46(8). 1713–1722. 9 indexed citations

17.

Kim, Jwa Hoon, Min‐Hee Ryu, Young Soo Park, et al.. (2019). Predictive biomarkers for the efficacy of nivolumab as ≥ third-line therapy in patients with advanced gastric cancer (AGC): From a subset analysis of ATTRACTION-2 phase III trial.. Journal of Clinical Oncology. 37(4_suppl). 152–152. 8 indexed citations

18.

Kim, Jwa Hoon, Sook Ryun Park, Min‐Hee Ryu, et al.. (2017). Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis. Cancer Research and Treatment. 50(2). 518–529. 10 indexed citations

19.

Kim, Jwa Hoon, Inkeun Park, & Jae‐Lyun Lee. (2016). Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features. Cancer Chemotherapy and Pharmacology. 78(2). 325–332. 16 indexed citations

20.

Kang, Byung Ju, et al.. (2015). A Critical Case of Wernicke's Encephalopathy Induced by Hyperemesis Gravidarum. SHILAP Revista de lepidopterología. 30(2). 128–131. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact